AmgenCHIX:AMGD 90 Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 950 Drug Manufacturers companies, Amgen ranks worse than 62.84% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Amgen's Revenue for the
three
months ended in Mar. 2026 was €7,455 Mil. Amgen's average Accounts Receivable for the
three
months ended in Mar. 2026 was €8,039 Mil.
Hence, Amgen's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.93.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Amgen Receivables Turnover Related Terms
Amgen Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Amgen's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMGD vs GILD, PFE, BMY: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Amgen's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Amgen's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (CHIX:AMGD) has a Receivables Turnover of 0.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Amgen and its competitors. According to the industry distribution chart, Amgen ranks #597 out of 950 companies in the Drug Manufacturers industry, placing it in the top 62.8%.
Is Amgen's Receivables Turnover too high?
Amgen's current Receivables Turnover is 0.93. The Drug Manufacturers industry median Receivables Turnover is 5.07. Amgen's value of 0.93 is 81.7% below this industry median. Based on the distribution chart, Amgen ranks #597 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Receivables Turnover compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #597 out of 950 companies for Receivables Turnover. This places Amgen in the lower half of its industry. The industry median Receivables Turnover is 5.07. Amgen's value of 0.93 is 81.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Receivables Turnover of 0.93 is 81.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Receivables Turnover is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current Receivables Turnover is 0.93 and 81.7% below the Drug Manufacturers industry median of 5.07. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
Receivables Turnover: 0.93
GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
Industry Position: 81.7% below the Drug Manufacturers median (#597 of 950)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score
Get the complete analysis for CHIX:AMGD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
